References

- Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974; 290: 697–701
- Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998; 9: S16–S23
- Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478–1483
- Seliger SL, Gillen DL, Longstreth WT,Jr, Kestenbaum B, Stehman-Breen CO. Elevated risk of stroke among patients with end-stage renal disease. *Kidney Int* 2003; 64: 603–609
- Collins AJ, Li S, Gilbertson DT *et al.* Chronic kidney disease and cardiovascular disease in the Medicare population. *Kidney Int* 2003; 64 [Suppl 87]: S24–S31
- Drey N, Roderick P, Mullee M, Rogerson M. A populationbased study of the incidence and outcomes of diagnosed chronic kidney disease. *Am J Kidney Dis* 2003; 42: 677–684
- 7. Best PJ, Holmes DR, Jr. Chronic kidney disease as a cardiovascular risk factor. *Am Heart J* 2003; 145: 383–386
- Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 1998; 339: 799–805
- 9. Herzog CA. Acute myocardial infarction in patients with end-stage renal disease. *Kidney Int* 1999; 56 [Suppl 71]: S130–S133
- United States Renal Data System. Patient mortality and survival. Am J Kidney Dis 1998; 32: S69–S80
- Dhingra H, Laski ME. Outcomes research in dialysis. Semin Nephrol 2003; 23: 295–305
- Reddan DN, Marcus RJ, Owen WF,Jr, Szczech LA, Landwehr DM. Long-term outcomes of revascularization for peripheral vascular disease in end-stage renal disease patients. *Am J Kidney Dis* 2001; 38: 57–63
- Holland DC, Lam M. Predictors of hospitalization and death among pre-dialysis patients: a retrospective cohort study. *Nephrol Dial Transplant* 2000; 15: 650–658
- Moeller S, Gioberge S, Brown G. ESRD patients in 2001: global overview of patients, treatment modalities and development trends. *Nephrol Dial Transplant* 2002; 17: 2071–2076
- Herzog CA. How to manage the renal patient with coronary heart disease: the agony and the ecstasy of opinion-based medicine. J Am Soc Nephrol 2003; 14: 2556–2572
- 16. Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154–2169
- Coresh J, Astor B, Sarnak MJ. Evidence for increased cardiovascular disease risk in patients with chronic kidney disease. *Curr Opin Nephrol Hypertens* 2004; 13: 73–81
- Pinkau T, Hilgers KF, Veelken R, Mann JF. How does minor renal dysfunction influence cardiovascular risk and the management of cardiovascular disease? J Am Soc Nephrol 2004; 15: 517–523
- Ritz E, McClellan WM. Overview: increased cardiovascular risk in patients with minor renal dysfunction: an emerging issue with far-reaching consequences. J Am Soc Nephrol 2004; 15: 513–516
- Bulpitt CJ, Beevers DG, Butler A *et al.* The survival of treated hypertensive patients and their causes of death: a report from the DHSS Hypertensive Care Computing Project (DHCCP). *J Hypertens* 1986; 4: 93–99
- Packer M, Carver JR, Rodeheffer RJ *et al.* Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. *N Engl J Med* 1991; 325: 1468–1475

- 22. Madsen BK, Hansen JF, Stokholm KH *et al.* Chronic congestive heart failure. Description and survival of 190 consecutive patients with a diagnosis of chronic congestive heart failure based on clinical signs and symptoms. *Eur Heart J* 1994; 15: 303–310
- 23. Spinar J, Vitovec J, Spac J et al. Non-invasive prognostic factors in chronic heart failure. One-year survival of 300 patients with a diagnosis of chronic heart failure due to ischemic heart disease or dilated cardiomyopathy. Int J Cardiol 1996; 56: 283–288
- 24. Rossing P, Hougaard P, Borch-Johnsen K, Parving HH. Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study. *Br Med J* 1996; 313: 779–784
- 25. Pahor M, Shorr RI, Somes GW et al. Diuretic-based treatment and cardiovascular events in patients with mild renal dysfunction enrolled in the systolic hypertension in the elderly program. Arch Intern Med 1998; 158: 1340–1345
- Feenstra J, in't Veld BA, van der Linden PD, Grobbee DE, Stricker BH. Risk factors for mortality in users of ibopamine. *Br J Clin Pharmacol* 1998; 46: 71–77
- 27. McAlister FA, Teo KK, Taher M *et al.* Insights into the contemporary epidemiology and outpatient management of congestive heart failure. *Am Heart J* 1999; 138: 87–94
- Opasich C, Tavazzi L, Lucci D *et al.* Comparison of one-year outcome in women *versus* men with chronic congestive heart failure. *Am J Cardiol* 2000; 86: 353–357
- 29. Cowie MR, Wood DA, Coats AJ *et al.* Survival of patients with a new diagnosis of heart failure: a population based study. *Heart* 2000; 83: 505–510
- Al Ahmad A, Rand WM, Manjunath G et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2001; 38: 955–962
- Wang JG, Staessen JA, Fagard RH *et al.* Prognostic significance of serum creatinine and uric acid in older Chinese patients with isolated systolic hypertension. *Hypertension* 2001; 37: 1069–1074
- Friedman PJ. Serum creatinine: an independent predictor of survival after stroke. J Intern Med 1991; 229: 175–179
- Nygard O, Nordrehaug JE, Refsum H et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230–236
- 34. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998; 339: 489–497
- Ting HH, Tahirkheli NK, Berger PB *et al.* Evaluation of longterm survival after successful percutaneous coronary intervention among patients with chronic renal failure. *Am J Cardiol* 2001; 87: 630–3, A9
- 36. Asinger RW, Henry TD, Herzog CA, Paulsen PR, Kane RL. Clinical outcomes of PTCA in chronic renal failure: a casecontrol study for comorbid features and evaluation of dialysis dependence. J Invasive Cardiol 2001; 13: 21–28
- 37. Januzzi JL,Jr, Snapinn SM, DiBattiste PM, Jang IK, Theroux P. Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. *Circulation* 2002; 105: 2361–2366
- Zebrack JS, Anderson JL, Beddhu S et al. Do associations with C-reactive protein and extent of coronary artery disease account for the increased cardiovascular risk of renal insufficiency? J Am Coll Cardiol 2003; 42: 57–63
- Reddan DN, Szczech LA, Tuttle RH *et al.* Chronic kidney disease, mortality, and treatment strategies among patients with clinically significant coronary artery disease. *J Am Soc Nephrol* 2003; 14: 2373–2380
- 40. Keeley EC, Kadakia R, Soman S, Borzak S, McCullough PA. Analysis of long-term survival after revascularization in

patients with chronic kidney disease presenting with acute coronary syndromes. Am J Cardiol 2003; 92: 509-514

- 41. Conlon PJ, Athirakul K, Kovalik E *et al.* Survival in renal vascular disease. *J Am Soc Nephrol* 1998; 9: 252–256
- 42. Naidu SS, Selzer F, Jacobs A *et al*. Renal insufficiency is an independent predictor of mortality after percutaneous coronary intervention. *Am J Cardiol* 2003; 92: 1160–1164
- 43. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. *Lancet* 2002; 360: 7–22
- Damsgaard EM, Froland A, Jorgensen OD, Mogensen CE. Microalbuminuria as predictor of increased mortality in elderly people. *Br Med J* 1990; 300: 297–300
- 45. Alcorn HG, Wolfson SK,Jr, Sutton-Tyrrell K, Kuller LH, O'Leary D. Risk factors for abdominal aortic aneurysms in older adults enrolled in The Cardiovascular Health Study. *Arterioscler Thromb Vasc Biol* 1996; 16: 963–970
- Bursztyn M, Ginsberg G, Spilberg O, Maaravi Y, Stessman J. Mortality in the Jerusalem 70-year-olds longitudinal study: does nifedipine have a role? *Geriatr Nephrol Urol* 1999; 9: 5–10
- Fried LF, Shlipak MG, Crump C et al. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol 2003; 41: 1364–1372
- Jungers P, Massy ZA, Khoa TN et al. Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: a prospective study. *Nephrol Dial Transplant* 1997; 12: 2597–2602
- 49. Jungers P, Nguyen KT, Massy ZA, Man NK. Incidence des accidents cardio-vasculaires d'origine athéromateuse chez l'urémique chronique: études épidemiologiques en Ile-de-France. Néphrologie 1998; 19: 489–494
- Levin A, Djurdjev O, Barrett B *et al.* Cardiovascular disease in patients with chronic kidney disease: getting to the heart of the matter. *Am J Kidney Dis* 2001; 38: 1398–1407
- Abramson JL, Jurkovitz CT, Vaccarino V, Weintraub WS, McClellan W. Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC Study. *Kidney Int* 2003; 64: 610–615
- Sadeghi HM, Stone GW, Grines CL et al. Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation 2003; 108: 2769–2775
- 53. McCullough PA, Nowak RM, Foreback C *et al.* Emergency evaluation of chest pain in patients with advanced kidney disease. *Arch Intern Med* 2002; 162: 2464–2468
- Langston RD, Presley R, Flanders WD, McClellan WM. Renal insufficiency and anemia are independent risk factors for death among patients with acute myocardial infarction. *Kidney Int* 2003; 64: 1398–1405
- 55. Scolari F, Ravani P, Pola A et al. Predictors of renal and patient outcomes in atheroembolic renal disease: a prospective study. J Am Soc Nephrol 2003; 14: 1584–1590
- 56. Hillege HL, van Gilst WH, van Veldhuisen DJ et al. Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial. Eur Heart J 2003; 24: 412–420
- Kaplan RC, Heckbert SR, Furberg CD, Psaty BM. Predictors of subsequent coronary events, stroke, and death among survivors of first hospitalized myocardial infarction. J Clin Epidemiol 2002; 55: 654–664
- Jurkovitz CT, Abramson JL, Vaccarino LV, Weintraub WS, McClellan WM. Association of high serum creatinine and anemia increases the risk of coronary events: results from the prospective community-based Atherosclerosis Risk in Communities (ARIC) Study. J Am Soc Nephrol 2003; 14: 2919–2925
- 59. Szczech LA, Best PJ, Crowley E *et al.* Outcomes of patients with chronic renal insufficiency in the bypass angioplasty revascularization investigation. *Circulation* 2002; 105: 2253–2258

- Al Suwaidi J, Reddan DN, Williams K et al. Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. *Circulation* 2002; 106: 974–980
- Matts JP, Karnegis JN, Campos CT *et al.* Serum creatinine as an independent predictor of coronary heart disease mortality in normotensive survivors of myocardial infarction. POSCH Group. *J Fam Pract* 1993; 36: 497–503
- Ruilope LM, Salvetti A, Jamerson K *et al.* Renal function and intensive lowering of blood pressure in hypertensive participants of the Hypertension Optimal Treatment (HOT) Study. *J Am Soc Nephrol* 2001; 12: 218–225
- 63. Shulman NB, Ford CE, Hall WD *et al.* Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the Hypertension Detection and Follow-up Program. The Hypertension Detection and Follow-up Program Cooperative Group. *Hypertension* 1989; 13: 180–193
- 64. Flack JM, Neaton JD, Daniels B, Esunge P. Ethnicity and renal disease: lessons from the Multiple Risk Factor Intervention Trial and the Treatment of Mild Hypertension Study. Am J Kidney Dis 1993; 21: 31–40
- 65. Manjunath G, Tighiouart H, Coresh J *et al.* Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. *Kidney Int* 2003; 63: 1121–1129
- Rao V, Weisel RD, Buth KJ et al. Coronary artery bypass grafting in patients with non-dialysis-dependent renal insufficiency. Circulation 1997; 96: II-43
- 67. Freeman RV, Mehta RH, Al Badr W *et al.* Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. *J Am Coll Cardiol* 2003; 41: 718–724
- Santopinto JJ, Fox KA, Goldberg RJ et al. Creatinine clearance and adverse hospital outcomes in patients with acute coronary syndromes: findings from the Global Registry of Acute Coronary Events (GRACE). *Heart* 2003; 89: 1003–1008
- Liu JY, Birkmeyer NJ, Sanders JH et al. Risks of morbidity and mortality in dialysis patients undergoing coronary artery bypass surgery. Northern New England Cardiovascular Disease Study Group. Circulation 2000; 102: 2973–2977
- Anderson RJ, O'Brien M, MaWhinney S et al. Mild renal failure is associated with adverse outcome after cardiac valve surgery. Am J Kidney Dis 2000; 35: 1127–1134
- O'Brien MM, Gonzales R, Shroyer AL et al. Modest serum creatinine elevation affects adverse outcome after general surgery. *Kidney Int* 2002; 62: 585–592
- Kennedy DJ, Colyer WR, Brewster PS *et al.* Renal insufficiency as a predictor of adverse events and mortality after renal artery stent placement. *Am J Kidney Dis* 2003; 42: 926–935
- Moscucci M, Kline-Rogers E, Share D et al. Simple bedside additive tool for prediction of in-hospital mortality after percutaneous coronary interventions. *Circulation* 2001; 104: 263–268
- 74. Shaw RE, Anderson HV, Brindis RG et al. Development of a risk adjustment mortality model using the American College of Cardiology–National Cardiovascular Data Registry (ACC–NCDR) experience: 1998–2000. J Am Coll Cardiol 2002; 39: 1104–1112
- Powell RJ, Roddy SP, Meier GH et al. Effect of renal insufficiency on outcome following infrarenal aortic surgery. Am J Surg 1997; 174: 126–130
- Soman SS, Sandberg KR, Borzak S *et al.* The independent association of renal dysfunction and arrhythmias in critically ill patients. *Chest* 2002; 122: 669–677
- 77. Gottdiener JS, Arnold AM, Aurigemma GP et al. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol 2000; 35: 1628–1637
- 78. Chae CU, Albert CM, Glynn RJ, Guralnik JM, Curhan GC. Mild renal insufficiency and risk of congestive heart failure in

CKD as cause of cardiovascular morbidity and mortality

men and women \geq 70 years of age. Am J Cardiol 2003; 92: 682–686

- Wang F, Dupuis JY, Nathan H, Williams K. An analysis of the association between preoperative renal dysfunction and outcome in cardiac surgery: estimated creatinine clearance or plasma creatinine level as measures of renal function. *Chest* 2003; 124: 1852–1862
- Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. *Transplantation* 2003; 75: 1291–1295
- Abbott KC, Yuan CM, Taylor AJ, Cruess DF, Agodoa LY. Early renal insufficiency and hospitalized heart disease after renal transplantation in the era of modern immunosuppression. *J Am Soc Nephrol* 2003; 14: 2358–2365
- Ojo AO, Held PJ, Port FK *et al.* Chronic renal failure after transplantation of a nonrenal organ. *N Engl J Med* 2003; 349: 931–940
- 83. Gerstein HC, Mann JF, Yi Q et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421–426
- Anderson RJ, O'Brien M, MaWhinney S et al. Renal failure predisposes patients to adverse outcome after coronary artery bypass surgery. VA Cooperative Study #5. Kidney Int 1999; 55: 1057–1062
- McCullough PA, Soman SS, Shah SS *et al.* Risks associated with renal dysfunction in patients in the coronary care unit. *J Am Coll Cardiol* 2000; 36: 679–684
- Rubenstein MH, Harrell LC, Sheynberg BV et al. Are patients with renal failure good candidates for percutaneous coronary revascularization in the new device era? *Circulation* 2000; 102: 2966–2972
- Beattie JN, Soman SS, Sandberg KR et al. Determinants of mortality after myocardial infarction in patients with advanced renal dysfunction. Am J Kidney Dis 2001; 37: 1191–1200
- Hemmelgarn BR, Ghali WA, Quan H et al. Poor long-term survival after coronary angiography in patients with renal insufficiency. Am J Kidney Dis 2001; 37: 64–72
- Shlipak MG, Simon JA, Grady D et al. Renal insufficiency and cardiovascular events in postmenopausal women with coronary heart disease. J Am Coll Cardiol 2001; 38: 705–711
- Szczech LA, Reddan DN, Owen WF et al. Differential survival after coronary revascularization procedures among patients with renal insufficiency. *Kidney Int* 2001; 60: 292–299
- Best PJ, Lennon R, Ting HH et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 2002; 39: 1113–1119
- Beddhu S, Allen-Brady K, Cheung AK *et al.* Impact of renal failure on the risk of myocardial infarction and death. *Kidney Int* 2002; 62: 1776–1783
- 93. Gruberg L, Weissman NJ, Waksman R et al. Comparison of outcomes after percutaneous coronary revascularization with stents in patients with and without mild chronic renal insufficiency. Am J Cardiol 2002; 89: 54–57
- Wright RS, Reeder GS, Herzog CA et al. Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann Intern Med 2002; 137: 563–570
- Walsh CR, O'Donnell CJ, Camargo CA,Jr, Giugliano RP, Lloyd-Jones DM. Elevated serum creatinine is associated with 1-year mortality after acute myocardial infarction. *Am Heart J* 2002; 144: 1003–1011
- 96. Gruberg L, Weissman NJ, Pichard AD *et al*. Impact of renal function on morbidity and mortality after percutaneous aortocoronary saphenous vein graft intervention. *Am Heart J* 2003; 145: 529–534
- 97. Reinecke H, Trey T, Matzkies F *et al.* Grade of chronic renal failure, and acute and long-term outcome after percutaneous coronary interventions. *Kidney Int* 2003; 63: 696–701

- Wison S, Foo K, Cunningham J et al. Renal function and risk stratification in acute coronary syndromes. Am J Cardiol 2003; 91: 1051–1054
- 99. Sorensen CR, Brendorp B, Rask-Madsen C et al. The prognostic importance of creatinine clearance after acute myocardial infarction. Eur Heart J 2002; 23: 948–952
- 100. Shlipak MG, Heidenreich PA, Noguchi H et al. Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med 2002; 137: 555–562
- 101. Brooks MM, Jones RH, Bach RG et al. Predictors of mortality and mortality from cardiac causes in the Bypass Angioplasty Revascularization Investigation (BARI) randomized trial and registry. For the BARI Investigators. *Circulation* 2000; 101: 2682–2689
- 102. Reis SE, Olson MB, Fried L *et al.* Mild renal insufficiency is associated with angiographic coronary artery disease in women. *Circulation* 2002; 105: 2826–2829
- 103. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000; 35: 681–689
- 104. Hillege HL, Girbes AR, de Kam PJ *et al.* Renal function, neurohormonal activation, and survival in patients with chronic heart failure. *Circulation* 2000; 102: 203–210
- 105. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. *Ann Intern Med* 2001; 134: 629–636
- 106. Schillaci G, Reboldi G, Verdecchia P. High-normal serum creatinine concentration is a predictor of cardiovascular risk in essential hypertension. *Arch Intern Med* 2001; 161: 886–891
- 107. Mahon NG, Blackstone EH, Francis GS et al. The prognostic value of estimated creatinine clearance alongside functional capacity in ambulatory patients with chronic congestive heart failure. J Am Coll Cardiol 2002; 40: 1106–1113
- 108. de Leeuw PW, Thijs L, Birkenhager WH et al. Prognostic significance of renal function in elderly patients with isolated systolic hypertension: results from the Syst-Eur trial. J Am Soc Nephrol 2002; 13: 2213–2222
- 109. Kearney MT, Fox KA, Lee AJ et al. Predicting death due to progressive heart failure in patients with mild-to-moderate chronic heart failure. J Am Coll Cardiol 2002; 40: 1801–1808
- 110. McClellan WM, Flanders WD, Langston RD, Jurkovitz C, Presley R. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J Am Soc Nephrol 2002; 13: 1928–1936
- 111. Manolio TA, Kronmal RA, Burke GL, O'Leary DH, Price TR. Short-term predictors of incident stroke in older adults. The Cardiovascular Health Study. *Stroke* 1996; 27: 1479–1486
- 112. Fried LP, Kronmal RA, Newman AB et al. Risk factors for 5-year mortality in older adults: the Cardiovascular Health Study. JAMA 1998; 279: 585–592
- Shlipak MG, Fried LF, Crump C et al. Cardiovascular disease risk status in elderly persons with renal insufficiency. *Kidney* Int 2002; 62: 997–1004
- 114. Wannamethee SG, Shaper AG, Perry IJ. Serum creatinine concentration and risk of cardiovascular disease: a possible marker for increased risk of stroke. *Stroke* 1997; 28: 557–563
- 115. Culleton BF, Larson MG, Wilson PW et al. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. *Kidney Int* 1999; 56: 2214–2219
- 116. Garg AX, Clark WF, Haynes RB, House AA. Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I. *Kidney Int* 2002; 61: 1486–1494
- 117. Muntner P, He J, Hamm L, Loria C, Whelton PK. Renal insufficiency and subsequent death resulting from

cardiovascular disease in the United States. J Am Soc Nephrol 2002; 13: 745–753

- 118. Henry RM, Kostense PJ, Bos G *et al.* Mild renal insufficiency is associated with increased cardiovascular mortality: the Hoorn Study. *Kidney Int* 2002; 62: 1402–1407
- 119. Manjunath G, Tighiouart H, Ibrahim H et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003; 41: 47–55
- 120. Landray MJ, Thambyrajah J, McGlynn FJ et al. Epidemiological evaluation of known and suspected cardiovascular risk factors in chronic renal impairment. Am J Kidney Dis 2001; 38: 537–546
- 121. Sarnak MJ, Coronado BE, Greene T *et al.* Cardiovascular disease risk factors in chronic renal insufficiency. *Clin Nephrol* 2002; 57: 327–335
- 122. Shoji T, Emoto M, Tabata T *et al*. Advanced atherosclerosis in predialysis patients with chronic renal failure. *Kidney Int* 2002; 61: 2187–2192
- 123. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. *Am J Kidney Dis* 2003; 41: 1–12
- 124. Harris MI, Flegal KM, Cowie CC *et al.* Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. The Third National Health and Nutrition Examination Survey, 1988–1994. *Diabetes Care* 1998; 21: 518–524
- 125. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. *Nature* 2001; 414: 782–787
- Uhlig K, Levey AS, Sarnak MJ. Traditional cardiac risk factors in individuals with chronic kidney disease. *Semin Dial* 2003; 16: 118–127
- 127. Locatelli F, Pozzoni P, Tentori F, del Vecchio L. Epidemiology of cardiovascular risk in patients with chronic kidney disease. *Nephrol Dial Transplant* 2003; 18 [Suppl 7]: vii2–vii9
- Cheung AK, Sarnak MJ, Yan G et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. *Kidney Int* 2000; 58: 353–362
- 129. Fleischmann EH, Bower JD, Salahudeen AK. Are conventional cardiovascular risk factors predictive of two-year mortality in hemodialysis patients? *Clin Nephrol* 2001; 56: 221–230
- Zoccali C. Cardiovascular risk in uraemic patients: is it fully explained by classical risk factors? *Nephrol Dial Transplant* 2000; 15: 454–457
- 131. Longenecker JC, Coresh J, Powe NR et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J Am Soc Nephrol 2002; 13: 1918–1927
- 132. Henle T, Miyata T. Advanced glycation end products in uremia. *Adv Ren Replace Ther* 2003; 10: 321–331
- Boaz M, Matas Z, Biro A et al. Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis. *Kidney Int* 1999; 56: 1078–1083
- 134. Boaz M, Smetana S, Weinstein T *et al.* Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. *Lancet* 2000; 356: 1213–1218
- 135. Boaz M, Matas Z, Biro A et al. Comparison of hemostatic factors and serum malondialdehyde as predictive factors for cardiovascular disease in hemodialysis patients. Am J Kidney Dis 1999; 34: 438–444
- 136. Siems W, Quast S, Carluccio F et al. Oxidative stress in chronic renal failure as a cardiovascular risk factor. Clin Nephrol 2002; 58 [Suppl 1]: S12–S19

- 137. Shoji T, Fukumoto M, Kimoto E *et al.* Antibody to oxidized low-density lipoprotein and cardiovascular mortality in end-stage renal disease. *Kidney Int* 2002; 62: 2230–2237
- 138. Shlipak MG, Fried LF, Crump C *et al.* Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. *Circulation* 2003; 107: 87–92
- 139. Stenvinkel P, Heimburger O, Jogestrand T. Elevated interleukin-6 predicts progressive carotid artery atherosclerosis in dialysis patients: association with *Chlamydia pneumoniae* seropositivity. *Am J Kidney Dis* 2002; 39: 274–282
- 140. London GM, Fabiani F, Marchais SJ et al. Uremic cardiomyopathy: an inadequate left ventricular hypertrophy. *Kidney Int* 1987; 31: 973–980
- 141. Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. *Nephrol Dial Transplant* 2000; 15: 1014–1021
- 142. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. *Am J Kidney Dis* 1998; 31: 607–617
- 143. Block G, Port FK. Calcium phosphate metabolism and cardiovascular disease in patients with chronic kidney disease. *Semin Dial* 2003; 16: 140–147
- 144. Zoccali C, Bode-Boger S, Mallamaci F et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. *Lancet* 2001; 358: 2113–2117
- 145. Zoccali C, Benedetto FA, Maas R et al. Asymmetric dimethylarginine, C-reactive protein, and carotid intimamedia thickness in end-stage renal disease. J Am Soc Nephrol 2002; 13: 490–496
- 146. De Boer IH, Gorodetskaya I, Young B, Hsu CY, Chertow GM. The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, race-dependent, and associated with cardiovascular disease. J Am Soc Nephrol 2002; 13: 2762–2769
- 147. Perkovic V, Hewitson TD, Kelynack KJ *et al.* Parathyroid hormone has a prosclerotic effect on vascular smooth muscle cells. *Kidney Blood Press Res* 2003; 26: 27–33
- 148. Zoccali C, Mallamaci F, Tripepi G et al. Prospective Study of Neuropeptide Y as an Adverse Cardiovascular Risk Factor in End-Stage Renal Disease. J Am Soc Nephrol 2003; 14: 2611–2617
- 149. Fellah H, Feki M, Hsairi M et al. Hyperhomocysteinemia and end-stage renal disease: determinants and association with cardiovascular disease in Tunisian patients. Clin Chem Lab Med 2003; 41: 675–680
- 150. Bostom AG, Shemin D, Verhoef P et al. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study. Arterioscler Thromb Vasc Biol 1997; 17: 2554–2558
- 151. Ducloux D, Motte G, Challier B, Gibey R, Chalopin JM. Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: a prospective study. J Am Soc Nephrol 2000; 11: 134–137
- Bostom AG, Culleton BF. Hyperhomocysteinemia in chronic renal disease. J Am Soc Nephrol 1999; 10: 891–900
- 153. Mallamaci F, Zoccali C, Tripepi G et al. Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. *Kidney Int* 2002; 61: 609–614
- 154. Moustapha A, Naso A, Nahlawi M et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. *Circulation* 1998; 97: 138–141
- 155. Rump LC, Amann K, Orth S, Ritz E. Sympathetic overactivity in renal disease: a window to understand progression and cardiovascular complications of uraemia? *Nephrol Dial Transplant* 2000; 15: 1735–1738

CKD as cause of cardiovascular morbidity and mortality

- 156. Jankowski J, van der GM, Jankowski V *et al.* Increased plasma phenylacetic acid in patients with end-stage renal failure inhibits iNOS expression. *J Clin Invest* 2003; 112: 256–264
- 157. Dou L, Bertrand E, Cerini C *et al.* The uremic solutes *p*-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. *Kidney Int* 2004; 65: 442–451
- 158. Glorieux GL, Dhondt AW, Jacobs P *et al. In vitro* study of the potential role of guanidines in leukocyte functions related to atherogenesis and infection. *Kidney Int* 2004; 65: 2184–2192
- 159. Vanholder R, de Smet R, Glorieux G et al. Review on uremic toxins: classification, concentration, and interindividual variability. *Kidney Int* 2003; 63: 1934–1943